Ipsen And Day One Enter Ex-U.S. Licensing Deal For Pediatric Brain Cancer Drug Tovorafenib
Portfolio Pulse from Benzinga Newsdesk
Ipsen has secured ex-U.S. rights to tovorafenib, a drug for pediatric brain cancer, from Day One. Day One will receive $111 million upfront and up to $350 million in milestone payments, plus royalties. The drug is FDA-approved for relapsed or refractory pediatric low-grade glioma and is undergoing a Phase III trial for newly diagnosed cases.
July 25, 2024 | 5:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One has entered a licensing deal with Ipsen for ex-U.S. rights to tovorafenib, receiving $111 million upfront and up to $350 million in milestone payments, plus royalties.
The deal provides significant immediate and potential future financial benefits to Day One, which could positively impact its stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Ipsen has secured ex-U.S. rights to tovorafenib, a drug for pediatric brain cancer, from Day One, enhancing its oncology portfolio.
The acquisition of ex-U.S. rights to a promising FDA-approved drug strengthens Ipsen's oncology portfolio, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100